Back to top

Here's Why Momentum Investors Will Love Aptevo Therapeutics Inc. (APVO)

Read MoreHide Full Article

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.

While many investors like to look for momentum in stocks, this can be very tough to define. There is a lot of debate surrounding which metrics are the best to focus on and which are poor quality indicators of future performance. The Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.

Below, we take a look at Aptevo Therapeutics Inc. (APVO - Free Report) , a company that currently holds a Momentum Style Score of B. We also talk about price change and earnings estimate revisions, two of the main aspects of the Momentum Style Score.

It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Aptevo Therapeutics Inc. Currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period.

You can see the current list of Zacks # 1 Rank Stocks here >>>

Set to Beat the Market?

Let's discuss some of the components of the Momentum Style Score for APVO that show why this company shows promise as a solid momentum pick.

A good momentum benchmark for a stock is to look at its short-term price activity, as this can reflect both current interest and if buyers or sellers currently have the upper hand. It's also helpful to compare a security to its industry; this can show investors the best companies in a particular area.

For APVO, shares are up 3.37% over the past week while the Zacks Medical - Biomedical and Genetics industry is up 3.09% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 22.4% compares favorably with the industry's 3.36% performance as well.

While any stock can see its price increase, it takes a real winner to consistently beat the market. That is why looking at longer term price metrics -- such as performance over the past three months or year -- can be useful as well. Over the past quarter, shares of Aptevo Therapeutics Inc. have risen 8.88%, and are up 154.38% in the last year. In comparison, the S&P 500 has only moved 5.93% and 19.01%, respectively.

Investors should also take note of APVO's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. Right now, APVO is averaging 108,465 shares for the last 20 days.

Earnings Outlook

The Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. Please note that estimate revision trends remain at the core of Zacks Rank as well. A nice path here can help show promise, and we have recently been seeing that with APVO.

Over the past two months, 2 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost APVO's consensus estimate, increasing from -$2.64 to -$2.42 in the past 60 days. Looking at the next fiscal year, 2 estimates have moved upwards while there have been no downward revisions in the same time period.

Bottom Line

Taking into account all of these elements, it should come as no surprise that APVO is a #2 (Buy) stock with a Momentum Score of B. If you've been searching for a fresh pick that's set to rise in the near-term, make sure to keep Aptevo Therapeutics Inc. On your short list.




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Aptevo Therapeutics Inc. (APVO) - free report >>

More from Zacks Tale of the Tape

You May Like